Patients similar to yours say NovoSeven® RT fits into their lives.

Hear about the quick access to treatment and fast infusion of NovoSeven® RT, and how MixPro® and compact packaging fit in when traveling the world.

(Left to right): Taylor has congenital factor VII hemophilia, and Justin and Bob have congenital hemophilia with inhibitors.

Patients similar to yours say NovoSeven® RT fits into their lives.

  • Meet Justin

    In this video, Justin, who lives with congenital hemophilia with inhibitors, talks about his love of travel, and how NovoSeven® RT fits in when he’s living life on the go. When he’s traveling internationally, the compact packaging of NovoSeven® RT is easy to take along.

  • Meet Bob

    In this video, you’ll hear from Bob about what it is like to live life with an inhibitor, and how important he finds the quick infusion time of NovoSeven® RT. Find out how NovoSeven® RT fits into his life.

  • Meet Chase

    Chase was diagnosed with hemophilia as an infant. In this video, Chase and his grandmother discuss his favorite activities and how the quick infusion time and portability of NovoSeven® RT fit into their lives.

  • Meet Taylor

    Taylor, who lives with congenital factor VII deficiency, loves to travel. Find out how the quick reconstitution of NovoSeven® RT fits in with the things she likes to do.

  • Meet Kali

    In this video, you'll hear from Kali about living with Glanzmann's thrombasthenia with refractoriness to platelets, and how she takes NovoSeven® RT along when she's on the go.

Patient brochures

Help patients learn

about hemophilia.


NovoSecure™ website

Product support for

patients.


HCP educational brochures

Educational materials

for you.

Selected Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported.
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT.
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis.

Indications and Usage

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and peri-operative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and peri-operative management in adults with acquired hemophilia

 

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported.
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT.
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis.

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance.
  • Exercise caution when administering NovoSeven® RT to patients with an increased risk of thromboembolic complications, such as those with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, crush injury, septicemia, uncontrolled post-partum hemorrhage, history of coronary heart disease, liver disease, post-operative immobilization, in elderly patients, in neonates, or in patients receiving concomitant treatment with aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates).
  • Hypersensitivity reactions, including anaphylaxis, have been reported with NovoSeven® RT. Administer only if clearly needed in patients with known hypersensitivity to NovoSeven® RT, any of its components, or mouse, hamster, or bovine proteins. Should symptoms occur, discontinue NovoSeven® RT and administer appropriate treatment.
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed.
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis.

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia.

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII.

Please click here for Prescribing Information.